

## Biophytis to Present the Preliminary Results of SARA-OBS and its Impact on SARA-INT, the Phase 2b clinical study, at the 10<sup>th</sup> International Conference on Frailty and Sarcopenia Research (ICFSR 2020) in Toulouse, France

Paris (France), Cambridge (Massachusetts, United States), March 3<sup>rd</sup>, 2020, 8:00 AM CET - Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company with a primary focus on the development of its lead drug candidate, Sarconeos (BIO101) for the treatment of neuromuscular diseases, announces that Biophytis management will make a presentation titled, "*SARA PROGRAM: PRELIMINARY FINDINGS & IMPLICATIONS FROM SARA-OBS STUDY AND ITS IMPACT ON SARA-INT STUDY*" at the 10th International Conference on Frailty and Sarcopenia Research (ICFSR 2020). The Conference is taking place between 11 and 13<sup>th</sup> March 2020 in Toulouse, France.

Biophytis' clinical development plan for Sarconeos (BIO101) for the treatment of sarcopenia comprises:

- SARA-PK, a Phase 1 clinical trial that showed safety and tolerability in older healthy volunteers. The trial completed in 2017.
- SARA-OBS, an observational trial that was completed in Q2 2019, and
- SARA-INT, an ongoing international Phase 2b trial with a 6-month follow-up period that is currently recruiting patients in the US and Europe. The primary endpoint of the study is the 400-meter walking test gait speed.

Biophytis presentation will:

- Outline the SARA-OBS study, which was designed to characterize, pre-recruit and confirm the optimal patient population for the SARA-INT trial, and
- Provide data on the preliminary baseline characteristics and changes from baseline of the first set of SARA-OBS patients.

In addition, insights on the SARA-INT recruitment strategies, including inclusion criteria, as well as the baseline characteristics of the first patients, will be discussed.

The presentation will be made Wednesday March 11<sup>th</sup> at 12:20 PM CET.

\*\*\*\*

### About BIOPHYTIS

Biophytis SA is a clinically staged biotechnology company specializing in the development of drug candidates to slow down degenerative processes and improve functional abilities in patients with age-related diseases, particularly neuromuscular diseases.

Sarconeos (BIO101), our leading drug candidate, is a small molecule, administered orally, currently in clinical

phase 2b in sarcopenia (SARA-INT) in the United States and Europe. A pediatric formulation of Sarconeos (BIO101) is being developed for the treatment of Duchenne myopathy (DMD) for which the company received IND status by the U.S. Food and Drug Administration (FDA) in December 2019.

The company is based in Paris, France, and Cambridge, Massachusetts. The company's common shares are listed on the Euronext Growth Paris market (Ticker: ALBPS -ISIN: FR0012816825). For more information [www.biophytis.com](http://www.biophytis.com).

#### **Disclaimer**

This press release contains forward-looking statements. While the Company considers its projections to be based on reasonable assumptions, these forward-looking statements may be called into question by a number of hazards and uncertainties, so that actual results may differ materially from those anticipated in such forward-looking statements. For a description of the risks and uncertainties likely to affect the results, BIOPHYTIS' financial position, performance or achievements and thus cause a change from the forward-looking statements, please refer to the "Risk Factors" section of the Company's Equity Admission Prospectus for listing on the Euronext Growth market in Paris filed with the AMF and available on the AMF ([www.amf-france.org](http://www.amf-france.org)) and BIOPHYTIS websites ([www.biophytis.com](http://www.biophytis.com)).

This press release, and the information contained in it, does not constitute an offer to sell or subscribe, nor the solicitation of a purchase or subscription order, of BIOPHYTIS shares in any country. The elements contained in this communication may contain forward-looking information involving risks and uncertainties. The Company's actual achievements may differ materially from those anticipated in this information due to different risk and uncertainty factors. This press release was written in French and English; If there is a difference between the texts, the French version will prevail.

#### **Biophytis Contact for Investor Relations**

Evelyne Nguyen, CFO

[evelyne.nguyen@biophytis.com](mailto:evelyne.nguyen@biophytis.com)

Tel: +33 1 44 27 23 32

#### **Media contact**

##### ***Citigate Dewe Rogerson***

Sylvie Berrebi/ Nathaniel Dahan/ David Dible / Quentin Dussart

[biophytis@citigatedewerogerson.com](mailto:biophytis@citigatedewerogerson.com)

Tel: +44 (0) 20 7638 9571 / +33 (0)1 55 30 70 91

Source : Biophytis